Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: A Randomized Controlled Proof-of-concept Study (PSILOTRAZ)

A 25-milligram dose of psilocybin, paired with trazodone, is being tested in a small clinical trial for people who haven’t responded to other treatments for depression. The trial, called PSILOTRAZ, is investigating whether this combination could offer new options for those with treatment-resistant depression — a condition that affects about 30% of people with major depressive disorder.

Bottom line: PSILOTRAZ is a small but ambitious trial testing if combining psilocybin with trazodone could offer new hope for people with treatment-resistant depression.

How a Mushroom and a Pill Might Rewrite the Rules of Depression

Depression is a disease of the brain, but it’s also a disease of the mind. For some, no amount of therapy, medication, or lifestyle change seems to cut through the fog. These are the people with treatment-resistant depression. For them, the standard antidepressants — like SSRIs or SNRIs — often fall flat.

Psilocybin, the psychoactive compound in magic mushrooms, has shown promise in reducing depressive symptoms. But it can also cause intense emotional experiences. Trazodone, a serotonin antagonist and reuptake inhibitor, is an approved prescription medicine for depression and insomnia. It’s also known for its sedative effects and ability to dampen the hallucinogenic experience of psilocybin.

The PSILOTRAZ study is testing whether combining the two could reduce the risk of adverse reactions while preserving the antidepressant effects of psilocybin.

The Science Behind the Psychedelic Antidepressant

Psilocybin works by interacting with serotonin receptors in the brain, particularly the 5-HT2A receptor. This receptor is found in high concentrations in the prefrontal cortex, a region linked to mood regulation and self-perception. When psilocybin binds to these receptors, it disrupts the brain’s default mode network, which is associated with rumination and negative thought patterns. This disruption may allow for a “reset” of the brain’s emotional circuits, leading to rapid and sustained improvements in mood.

But not everyone responds the same way. Some people report profound, life-changing experiences, while others feel overwhelmed or confused. This variability is why researchers are interested in how trazodone might modulate psilocybin’s effects.

Trazodone is a 5-HT2A antagonist, meaning it blocks these receptors. In a 2023 study by Rosenblat et al., researchers found that pre-administration of trazodone could eliminate the acute subjective effects of psilocybin — like the intense emotional highs and lows — without affecting its antidepressant properties. This suggests that the psychedelic experience might not be necessary for the therapeutic benefit of psilocybin.

The PSILOTRAZ study builds on this finding. It’s not just about whether trazodone reduces the “bad” parts of psilocybin — it’s about whether it enhances the “good” parts. If trazodone can reduce the risk of adverse reactions while preserving the antidepressant effects, it could make psilocybin a safer, more accessible treatment option for people with treatment-resistant depression.

What the Trial Might Tell Us About the Brain

The PSILOTRAZ study is testing two different doses of trazodone — one that provides partial occupancy of 5-HT2A receptors and one that offers total occupancy — to see how each affects the benefit-risk ratio of psilocybin. This is important because it could help researchers understand whether the psychedelic experience is a necessary component of psilocybin’s antidepressant effects or if the compound’s impact on other serotonin receptors is sufficient.

The study also highlights the growing interest in how psychedelic compounds interact with the brain’s neurochemical systems. While psilocybin is known for its 5-HT2A activity, it also affects other serotonin receptors, including 5-HT1A and 5-HT2C. These receptors are involved in mood regulation, neuroplasticity, and the modulation of stress responses.

By studying how trazodone interacts with these systems, researchers hope to uncover new pathways for treating depression.

Moreover, the study’s focus on treatment-resistant depression is significant. This group of patients has historically been difficult to treat, and many have not responded to traditional antidepressants. If psilocybin and trazodone can offer a new approach, it could represent a paradigm shift in the treatment of mood disorders. But it’s also a reminder that the brain is complex, and what works for one person may not work for another.

Frequently Asked Questions

Q: Is psilocybin safe?
A: Psilocybin is generally considered safe when used in controlled, therapeutic settings. However, it can cause intense emotional experiences, and some people may feel overwhelmed or anxious. The PSILOTRAZ study is designed to mitigate these risks by pairing psilocybin with trazodone, which may reduce the intensity of the psychedelic experience.

Q: What about the placebo effect?
A: The study uses a double-blind, placebo-controlled design to account for the placebo effect. Participants are randomly assigned to receive either psilocybin with trazodone, psilocybin alone, or a placebo. This helps ensure that any observed effects are due to the treatment rather than psychological factors.

Q: How long does the trial last?
A: The trial is expected to last several months, with follow-up assessments to monitor the long-term effects of the treatment. The exact duration is still being determined, but the study is designed to gather both short-term and long-term data.

Q: Can I participate in the study?
A: Participation is limited to patients with treatment-resistant depression who meet the study’s inclusion criteria. The study is currently recruiting participants, and interested individuals can contact the Centre Hospitalier St Anne for more information.

Sources

• ¶PSILOTRAZ Study on ClinicalTrials.gov
• ¶Rosenblat, G. D., et al. (2023). The Role of 5-HT2A Receptors in the Antidepressant Effects of Psilocybin. Journal of Psychopharmacology.
• ¶ClinicalTrials.gov: A registry of federally and privately supported clinical studies conducted in the United States and around the world.

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.